Program
centanafadine hydrochloride
Also written as “Centanafadine”, “Centanafadine SR” and “EB-1020 (Centanafadine) 164.4 mg”.
Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Depressive Disorder, Major · Drug Misuse · Binge-Eating Disorder · Smoking Cessation, led by Otsuka.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 255 open or running | phase 3since Jun 28, 2018 | Nov 19, 2012 | May 27, 2027phase 3 · NCT07759154 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Nov 19, 2012.
- Feb 25, 2021Phase 1 study in Attention Deficit Disorder with HyperactivityNCT04786730 · 50 enrolled · United States
- Sep 23, 2021Phase 2 study in Smoking CessationNCT05066724 · 50 enrolled · United States
- Oct 7, 2021Phase 2 study in Binge-Eating DisorderNCT05113953 · 147 enrolled · United States
- Feb 16, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityNCT05257265 · 459 enrolled · United States
- Mar 4, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityNCT05279313 · 680 enrolled · United States, Canada, Puerto Rico
- Jun 16, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityNCT05428033 · 574 enrolled · United States
- Sep 7, 2022Phase 2 study in Depressive Disorder, MajorNCT05536414 · 337 enrolled · United States
- Apr 9, 20252 phase 3 studies in Attention Deficit Disorder with HyperactivityNCT06931080, NCT06926829
- May 7, 2025Phase 3 study in Attention Deficit Disorder with HyperactivityNCT06973577 · 315 enrolled · United States, Puerto Rico
- Jul 17, 20252 phase 3 studies in Attention Deficit Disorder with HyperactivityNCT07086313, NCT07087327
- Nov 19, 2025Phase 1 study in Attention Deficit Disorder with HyperactivityNCT07253441 · 174 enrolled · United States
- Dec 18, 2025Phase 1 study in Attention Deficit Disorder with HyperactivityNCT07314333 · 40 enrolled · United States
- Mar 6, 20262 phase 1 studiesNCT07465731, NCT07486895
- Aug 6, 2026Phase 3 study in Attention Deficit Disorder with HyperactivityNCT07759154 · 80 planned · United States
Ahead
- May 27, 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT07759154
- Aug 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT07087327
- Aug 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT07086313
- Dec 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityNCT06926829
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07759154Attention Deficit Disorder with Hyperactivity · United States | 3 | Recruiting | May 27, 2027 | 80 |
| NCT07486895Attention Deficit Disorder with Hyperactivity · United States | 1 | Completed | May 18, 2023 | 44 |
| NCT07465731Healthy Volunteers · United States | 1 | Completed | Mar 26, 2023 | 62 |
| NCT07314333Attention Deficit Disorder with Hyperactivity · United States | 1 | Completed | Mar 30, 2026 | 40 |
| NCT07253441Attention Deficit Disorder with Hyperactivity · United States | 1 | Completed | Dec 30, 2024 | 174 |
| NCT07087327Attention Deficit Disorder with Hyperactivity · Japan | 3 | Recruiting | Aug 2027 | 180 |
| NCT07086313Attention Deficit Disorder with Hyperactivity · Japan | 3 | Recruiting | Aug 2027 | 315 |
| NCT06973577Attention Deficit Disorder with Hyperactivity · United States, Puerto Rico | 3 | Completed | Apr 22, 2026 | 315 |
| NCT06926829Attention Deficit Disorder with Hyperactivity · Japan | 3 | Recruiting | Dec 2027 | 180 |
| NCT06931080Attention Deficit Disorder with Hyperactivity · Japan | 3 | Recruiting | Dec 2027 | 630 |
| NCT05536414Depressive Disorder, Major · United States | 2 | Completed | May 16, 2025 | 337 |
| NCT05428033Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Mar 17, 2025 | 574 |
| NCT05279313Attention Deficit Disorder with Hyperactivity · United States, Canada, Puerto Rico | 3 | Completed | Apr 24, 2026 | 680 |
| NCT05257265Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Sep 29, 2023 | 459 |
| NCT05113953Binge-Eating Disorder · United States | 2 | Completed | Aug 19, 2022 | 147 |
| NCT05066724Smoking Cessation · United States | 2 | Completed | May 31, 2022 | 50 |
| NCT04786730Attention Deficit Disorder with Hyperactivity · United States | 1 | Completed | Apr 26, 2023 | 50 |
| NCT04398225Attention Deficit Disorder with Hyperactivity · United States | 1 | Completed | Apr 1, 2021 | 32 |
| NCT04081363Attention Deficit Disorder with Hyperactivity · United States | 2 | Completed | Dec 21, 2019 | 13 |
| NCT03605849Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Sep 7, 2021 | 662 |
| NCT03605836Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | May 14, 2020 | 590 |
| NCT03605680Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Apr 11, 2020 | 604 |
| NCT02827513Attention Deficit Disorder with Hyperactivity · Australia | 1 | Terminated | Jan 2016 | 16 |
| NCT02144415Drug Misuse · United States | 1 | Completed | Jul 1, 2014 | 80 |
| NCT01744808Normal, Healthy Volunteers · Australia | 1 | Completed | Feb 1, 2014 | 54 |
How it is read
Names in the registry
- “Centanafadine”, 9 entries
- “Centanafadine SR”, 6 entries
- “EB-1020 (Centanafadine) 164.4 mg”, 2 entries
- “EB-1020 (Centanafadine) 328.8 mg”, 2 entries
- “Centanafadine Hydrochloride”, 2 entries
Conditions, from the studies’ own filings
- Attention Deficit Disorder with Hyperactivity, 19 studies
- Depressive Disorder, Major, 1 study
- Drug Misuse, 1 study
- Binge-Eating Disorder, 1 study
- Smoking Cessation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.